The supplement aisle and the clinical pharmacy both promise to raise NAD+, but the products on each shelf are not the same molecule, and they do not behave the same way in the body. Understanding the difference is the work of ten minutes and saves a lot of money. This article walks through what NAD+, NMN, and NR actually are, how each reaches the cell, and why prescribed NAD+ therapy delivered subcutaneously occupies a different category from oral NAD+ precursors sold over the counter.
The bottom line up front: all three molecules can raise tissue NAD+. The amount of bioavailable molecule that reaches peripheral tissues per dollar spent differs by an order of magnitude depending on the form and the route. The right product for a given patient depends on their clinical picture, their goals, and their tolerance for cost-per-effective-dose. The marketing rarely answers that question honestly.
The three molecules on the same pathway
NAD+ is the active coenzyme. Cells use it directly in redox reactions, sirtuin signaling, and DNA-repair chemistry. NMN (nicotinamide mononucleotide) sits one step upstream. The enzyme NMNAT phosphorylates NMN to produce NAD+ inside the cell. NR (nicotinamide riboside) sits one step further upstream. The enzyme NRK phosphorylates NR to produce NMN, which is then converted to NAD+ as above.
So the conversion order is: NR → NMN → NAD+. Each step requires its own enzyme, its own substrate availability, and its own cellular energy. The cell can use any of the three as input, but the further upstream the input is, the more cellular machinery is required to deliver active NAD+ where it is needed.
The supplement industry has compressed this into the phrase "NAD+ booster," which collapses the distinctions. A clinician evaluating these products sees three different molecules with three different stability profiles, three different absorption rates, and three different first-pass metabolism patterns. The choice between them is a pharmacokinetic decision, not a brand decision.
What "bioavailability" actually means here
Bioavailability is the fraction of an administered dose that reaches systemic circulation in active form. For oral medications, bioavailability is reduced by three factors: incomplete absorption across the gut wall, degradation by digestive enzymes, and first-pass metabolism in the liver before the molecule reaches peripheral tissues.
Oral NAD+ itself fares badly on all three counts. The molecule is large, charged, and unstable in gastric acid. Most of an oral NAD+ capsule is broken down before any of it reaches blood. This is why clinical protocols rarely use oral NAD+; the math does not justify the dose.
NR and NMN are smaller and more stable, so they survive the gut better. Both are absorbed reasonably well. The bottleneck is the liver. First-pass hepatic metabolism converts a meaningful fraction of an oral precursor dose into nicotinamide before the molecule can reach muscle, brain, or skin. Some of that nicotinamide is eventually recycled back into NAD+ through the salvage pathway, but the conversion is inefficient, and the tissue distribution is different from what would be achieved by a parenteral route.
The practical consequence: a 1,000 mg oral NMN capsule does not equal 1,000 mg of subcutaneous NAD+. The active concentration arriving at peripheral tissues is lower, sometimes substantially lower. Reported bioavailability for high-quality oral NR products in human trials runs in a low-double-digit percentage range. Subcutaneous administration sidesteps this entirely.
Why subcutaneous NAD+ outperforms oral precursors
A subcutaneous injection deposits the molecule in the fatty tissue layer below the skin, from which it diffuses into local capillaries and enters venous return without passing through the gut or being filtered by the liver before reaching systemic circulation. This route preserves the dose. Whatever the clinician dispenses arrives at circulation in close-to-full concentration, distributed across the body's vascular bed.
For NAD+ specifically, this matters because the molecule itself is what the cell uses. Skipping the conversion steps from NR or NMN means the cell does not need to expend ATP, NRK, NMNAT, or any of the other enzymatic infrastructure to convert a precursor into the active form. The molecule arrives ready to participate in redox reactions and sirtuin chemistry directly.
This is not theoretical. Clinical observation across prescribed NAD+ protocols consistently shows faster onset of subjective effects compared with oral precursor regimens. Patients describe energy and recovery changes within the first few weeks rather than the longer ramp typical of oral NR. The mechanism is consistent with the pharmacokinetics: the active molecule reaches tissue at higher concentrations, and the cell does not have to do the conversion work.
The cost-per-effective-dose math
A premium oral NMN supplement at clinical-grade dosing — say 1,000 mg per day — typically costs in the range of $80 to $150 per month. A prescribed subcutaneous NAD+ protocol at a typical clinical cadence runs $200 to $400 per month depending on dose and frequency. On nominal price the supplement is cheaper.
On effective dose the calculation flips. If oral bioavailability is in the low-double-digits and subcutaneous bioavailability is essentially complete, the supplement at $100 per month is delivering the equivalent of perhaps 100 to 150 mg of active molecule. The injectable protocol at $300 per month is delivering meaningfully more active molecule at the tissue level, plus the clinician oversight, plus the lab review, plus the ability to titrate dose against patient-reported response.
The cost-per-tissue-NAD+-rise is the right metric for someone who has already decided to spend money on this category. For patients further upstream in the decision — those still deciding whether NAD+ is worth pursuing at all — the cheaper supplement trial is a reasonable first step. For patients who have done that trial and want a better answer, the math points toward the prescribed route.
Where each form fits in a clinical protocol
Oral NR or NMN works as a foundation for younger patients with mild complaints, or as a maintenance layer between courses of injectable NAD+ for patients who use the prescribed route episodically rather than continuously. The precursor pathway is real, the trial data is the strongest in the category, and the products are widely available.
Prescribed subcutaneous NAD+ fits patients whose clinical picture justifies the higher dose and the closer monitoring — persistent fatigue not resolved by oral trials, recovery athletes, longevity-focused patients who want a measurable mitochondrial input. The clinician determines candidacy, dose, and cadence based on history, goals, and labs.
IV NAD+ exists as a third option and produces a different concentration curve again — higher peak, faster delivery, and a more intense subjective profile. It also requires an in-clinic infusion and costs more per session. For most patients the subcutaneous route delivers the bulk of the benefit at a fraction of the logistical and financial cost.
A note on FDA status
None of these are FDA-approved drugs for NAD+ deficiency or anti-aging indications. FDA approved NAD+ as a category does not exist; there is no NAD+ drug approved for these uses. Oral NR and NMN are sold as dietary supplements, regulated as such. Compounded NAD+ preparations are made by licensed 503A pharmacies in response to specific patient prescriptions. Compounded medications are not FDA-approved. This is not a loophole; it is the standard regulatory framework that applies to a wide range of legitimate clinical preparations. The relevant question for a patient is whether a licensed clinician has reviewed their case and determined the protocol is appropriate.
How TelePeptide handles this decision
A licensed clinician reviews each patient's case and determines whether oral precursors, prescribed subcutaneous NAD+, or no NAD+ at all is the right starting point. The recommendation is based on clinical picture, not on what the patient asks for by name. Pricing is transparent and locked at the founder rate; the dose and route decision is the clinician's. Compounded preparations are sourced from licensed 503A pharmacies. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved.
FAQ
Common questions
What is the difference between NAD+, NMN, and NR?
They are three molecules on the same pathway. NAD+ is the active coenzyme that cells use directly. NMN (nicotinamide mononucleotide) is one chemical step upstream — the cell converts it to NAD+ via the NMNAT enzyme. NR (nicotinamide riboside) is one step further upstream than NMN — the cell phosphorylates it to NMN first, then converts NMN to NAD+. The marketing collapses this into "NAD+ boosters" but the molecules behave differently in the body. The choice of which to use is a pharmacokinetic question about how much of the active form actually reaches cells in usable concentrations.
Which precursor has the most human data?
NR has the longer track record in randomized controlled trials. Multiple studies in adults have shown that NR raises whole-blood NAD+ measurably and sustains the increase across weeks of dosing. NMN has a growing trial base, more recent, with consistent direction but a smaller cumulative sample size. Direct NAD+ has the smallest controlled-trial footprint but the most clinical observation experience in licensed settings. None of these are FDA-approved drugs. They are sold as supplements, except when a licensed clinician prescribes a compounded preparation under physician supervision.
Why is bioavailability so much lower for oral forms?
Oral NAD+ itself is largely hydrolyzed in the digestive tract before it can cross the intestinal wall intact. The molecule is too charged and too unstable to survive gastric acid and pancreatic enzymes in meaningful quantity. Precursors do better because they are smaller and more stable, but they still pass through the liver, where first-pass metabolism reduces what reaches peripheral tissues. The fraction of an oral dose that actually arrives at muscle, brain, or skin in active form is a small percentage of what was swallowed. Subcutaneous administration bypasses both the gut wall and the first-pass liver effect.
Is more expensive better?
Not automatically. Cost-per-effective-dose is the right calculation. A 1,000 mg oral NMN capsule is not equivalent to 1,000 mg of subcutaneous NAD+ because the bioavailable fractions are different. When the math is done on a per-tissue-NAD+-rise basis — using the precursor-trial data and the parenteral observation data — clinical-grade injectable protocols typically deliver more bioavailable molecule per dollar than premium oral supplements, even at the higher per-vial price point. The actual answer depends on the patient and the dose.
Should someone just take a supplement first?
For some patients, yes. A trial of a well-formulated oral NR or NMN product over a defined period is reasonable as a first step, particularly for younger patients with milder fatigue complaints and no other indications. For patients who have already done that and seen limited response, or who present with the clinical picture that prescribed NAD+ is meant to address, the question becomes whether to continue spending on a low-bioavailability route or move to a clinically supervised parenteral protocol. A licensed clinician makes this call individually.
Next Step
Talk to a TelePeptide Clinician
A licensed clinician will review your goals and recommend the right protocol — peptide wellness, recomposition, or supervised weight loss. No insurance, no waiting room.
TelePeptide offers direct-pay telehealth services. All medications are compounded by licensed 503A pharmacies. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved.